| Literature DB >> 30875899 |
Pierre-Eric Campos1, Emmanuel Pichon2, Céline Moriou3, Patricia Clerc4, Rozenn Trépos5, Michel Frederich6, Nicole De Voogd7, Claire Hellio8, Anne Gauvin-Bialecki9, Ali Al-Mourabit10.
Abstract
Chemical study of the CH₂Cl₂-MeOH (1:1) extract of the sponge Fascaplysinopsis reticulata collected in Mayotte highlighted three new tryptophan derived alkaloids, 6,6'-bis-(debromo)-gelliusine F (1), 6-bromo-8,1'-dihydro-isoplysin A (2) and 5,6-dibromo-8,1'-dihydro-isoplysin A (3), along with the synthetically known 8-oxo-tryptamine (4) and the three known molecules from the same family, tryptamine (5), (E)-6-bromo-2'-demethyl-3'-N-methylaplysinopsin (6) and (Z)-6-bromo-2'-demethyl-3'-N-methylaplysinopsin (7). Their structures were elucidated by 1D and 2D NMR spectra and HRESIMS data. All compounds were evaluated for their antimicrobial and their antiplasmodial activities. Regarding antimicrobial activities, the best compounds are (2) and (3), with minimum inhibitory concentration (MIC) of 0.01 and 1 µg/mL, respectively, towards Vibrio natrigens, and (5), with MIC values of 1 µg/mL towards Vibrio carchariae. In addition the known 8-oxo-tryptamine (4) and the mixture of the (E)-6-bromo-2'-demethyl-3'-N-methylaplysinopsin (6) and (Z)-6-bromo-2'-demethyl-3'-N-methylaplysinopsin (7) showed moderate antiplasmodial activity against Plasmodium falciparum with IC50 values of 8.8 and 8.0 µg/mL, respectively.Entities:
Keywords: Fascaplysinopsis reticulata; antimalarial activity; antimicrobial activity; marine sponge; tryptamine alkaloids
Mesh:
Substances:
Year: 2019 PMID: 30875899 PMCID: PMC6471642 DOI: 10.3390/md17030167
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–7.
1D and 2D NMR spectroscopic data (1H, 13C 300 MHz, CD3OD) for 6,6′-bis-(debromo)-gelliusine F (1).
| Position | δC, Type | δH ( | COSY (1H-1H) | HMBC (1H-13C) |
|---|---|---|---|---|
| 2 | 124.0, C | - | - | - |
| 3 | 113.8, C | - | - | - |
| 3a | 127.5, C | - | - | - |
| 4 | 118.9, CH | 7.54, d (7.8) | 5 | 6, 7a |
| 5 | 112.6, CH | 7.38, m | 4, 6 | 3a, 7 |
| 6 | 123.1, CH | 7.12, m | 5, 7 | 4, 7a |
| 7 | 120.7, CH | 7.06, m | 6 | 3a, 5 |
| 7a | 135.3, C | - | - | - |
| 8 | 23.7, CH2 | 3.23, m | 9 | 2, 3, 3a, 9 |
| 9 | 41.4, CH2 | 3.00, m | 8 | 3, 8 |
| 2′ | 124.0, CH | 7.27, s | - | 3′, 3a’, 7a’ |
| 3′ | 113.7, C | - | - | - |
| 3a’ | 129.2, C | - | - | - |
| 4′ | 119.3, CH | 7.58, d (7.8) | 5′ | 6′, 7a’ |
| 5′ | 112.9, CH | 7.41, m | 4′, 6′ | 3a’, 7′ |
| 6′ | 123.3, CH | 7.14, m | 5′, 7′ | 4′, 7a’ |
| 7′ | 120.6, CH | 7.06, m | 6′ | 3a’, 5′ |
| 7a’ | 138.0, C | - | - | - |
| 8′ | 34.3, CH | 5.10, t (8.6) | 9′ | 2′, 3′, 3a’, 9′ |
| 9′ | 44.3, CH2 | 3.83–3.69 (m) | 8′ | 3′, 8′ |
Figure 2Key COSY and HMBC correlations for compounds 1 and 2.
1D and 2D NMR spectroscopic data (1H, 13C 300 MHz, CD3OD) for 6-bromo-8,1′-dihydro-isoplysin A (2).
| Position | δC, Type | δH ( | COSY (1H-1H) | HMBC (1H-13C) |
|---|---|---|---|---|
| 2 | 126.4, CH | 7.11, s | - | 3, 3a, 7a, 8 |
| 3 | 109.0, C | - | - | - |
| 3a | 127.6, C | - | - | - |
| 4 | 121.1, CH | 7.51, d (8.6) | 5 | 6, 7a |
| 5 | 123.3, CH | 7.14, dd (8.6, 1.8) | 4 | 3a, 7 |
| 6 | 116.6, C | - | - | - |
| 7 | 115.5, CH | 7.50, d (1.8) | - | 3a, 5 |
| 7a | 138.1, C | - | - | - |
| 8 | 28.1, CH2 | 3.35, m | 1′ | - |
| 1′ | 61.8, CH | 4.62, t (4.9) | 8 | 5′, 8 |
| 3′ | 159.2, C | - | - | - |
| 5′ | 174.9, C | - | - | - |
| 6′ | 25.9, CH3 | 2.90, s | - | 3′ |
| 7′ | 29.3, CH3 | 2.86, s | -’ | 3′, 5′ |
Comparison of 1D NMR Spectroscopic Data (1H, 13C 300 MHz, CD3OD for (2) and 1H 500 MHz, 13C 600 MHz, CD3OD for (3)) between 6-bromo-8,1′-dihydro-isoplysin A (2) and 5,6-dibromo-8,1′-dihydro-isoplysin A (3).
| Position | δH ( | δC, Type | ||
|---|---|---|---|---|
| 6-Bromo-8,1′-dihydro-isoplysin A (2) | 5,6-Dibromo-8,1′-dihydro-isoplysin A (3) | 6-Bromo-8,1′-dihydro-isoplysin A (2) | 5,6-Dibromo-8,1′-dihydro-isoplysin A (3) | |
| 2 | 7.11, s | 7.16, s | 126.4, CH | 126.6, CH |
| 3 | - | - | 109.0, C | 109.0, C |
| 3a | - | - | 127.6, C | 129.8, C |
| 4 | 7.51, d (8.6) | 7.96, s | 121.1, CH | 123.6, CH |
| 5 | 7.14, dd (8.6, 1.8) | - | 123.3, CH | 116.9, C |
| 6 | - | - | 116.6, C | 115.9, C |
| 7 | 7.50, d (1.8) | 7.69, s | 115.5, CH | 117.4, CH |
| 7a | - | - | 138.1, C | 137.5, C |
| 8 | 3.35, m | 3.73, m | 28.1, CH2 | 28.2, CH2 |
| 1′ | 4.62, t (4.9) | 4.60, t (5.3) | 61.8, CH | 61.4, CH |
| 3′ | - | - | 159.2, C | 157.9, C |
| 5′ | - | - | 174.9, C | 175.8, C |
| 6′ | 2.90, s | 2.86, s | 25.9, CH3 | 25.4, CH3 |
| 7′ | 2.86, s | 2.94, s | 29.3, CH3 | 28.9, CH3 |
Antimicrobial activities in vitro for pure isolated natural products.
| Compounds | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A | G | A | G | A | G | A | G | A | G | |
| 6,6′-bis-(debromo)-gelliusine F ( | - | - | - | - | - | - | - | - | - | - |
| 6-bromo-8,1′-dihydro-isoplysin A ( | - | 100 | - | - | 100 | - | 100 | 0.01 | - | - |
| 5,6-dibromo-8,1′-dihydro-isoplysin A ( | - | - | - | - | - | - | - | 1 | - | - |
| 8-oxo-tryptamine ( | - | - | - | - | - | - | - | - | - | - |
| tryptamine ( | - | - | - | - | - | 1 | - | - | - | - |
| ( | - | - | - | - | - | - | - | - | - | - |
A: Adhesion inhibition; G: Growth inhibition.